GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
February 06, 2020 09:00 ET
|
GeoVax, Inc.
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology...